Loading...
ProKidney Corp.
PROK•NASDAQ
HealthcareBiotechnology
$0.98
$0.19(24.22%)
ProKidney Corp. (PROK) Stock Overview
Explore ProKidney Corp.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.53
↓ 72.51%
EPS Growth
$-0.53
↑ 15.79%
Operating Margin
-60453.59%
↓ 21.22%
ROE
6.94%
↓ 72.51%
Dividend Yield
0.00%
Analyst Recommendations
Strong Buy
Buy
Hold
Sell
Strong Sell
Price Targets
Low$3.00
Average$4.67
High$6.00
Company Profile
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
CEO
Dr. Bruce Culleton M.D.
Employees
204
Headquarters
2000 Frontis Plaza Blvd., Winston-Salem, NC
Founded
2021